CD274 and urothelial carcinoma: To validate the predictive capability of RPS regarding patient outcomes after immunotherapy, we selected the urothelial carcinoma dataset (IMvigor210) and the advanced NSCLC dataset treated with anti-PD-L1 (GSE135222) as the validation datasets.